Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)

NCT: NCT05345444 · ACTIVE_NOT_RECRUITING

NCT IDNCT05345444
StatusACTIVE_NOT_RECRUITING
Start Date2022-05-26
Completion2027-08
SponsorWeill Medical College of Cornell University (OTHER)
First posted
Last updated

Brief Summary

This is a single-site trial for 42 subjects with intermediate risk prostate cancer who undergo Irreversible Electroporation (IRE) followed by Magnetic Resonance guided Radiotherapy MRgRT. The investigators hypothesize that the combined therapy will feasible and be safe to perform with low morbidity. Ultimately, RTIRE may provide optimal treatment for intermediate risk prostate cancer patients.

Frequently Asked Questions

What is Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)?

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) is a clinical trial registered under NCT05345444. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05345444?

The current status of NCT05345444 (Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)) is: ACTIVE_NOT_RECRUITING.

When did Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) start?

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE) started on 2022-05-26.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑